CLOs on the Move

"Population Diagnostics Inc. (PDx) is a molecular diagnostics and personalized medicine company whose central objectives are (i) to develop DNA based pre-symptomatic and early detection tests for Autism, Alzheimer's, Parkinson's, Type 2 Diabetes and other genetic diseases and (ii) to develop ""Companion Tests"", which predict the efficacy and/or safety of a drug in a patient prior to the administration of a drug. PDx's proprietary technology can be universally applied to finding the genetic causes to any inherited or sporadic genetic disease. When applied to personalizing medicine, the technology standardizes the pharmaceutical industry's approach to generating clinically useful genetic profiles used ...

"Population Diagnostics Inc. (PDx) is a molecular diagnostics and personalized medicine company whose central objectives are (i) to develop DNA based pre-symptomatic and early detection tests for Autism, Alzheimer's, Parkinson's, Type 2 Diabetes and other genetic diseases and (ii) to develop ""Companion Tests"", which predict the efficacy and/or safety of a drug in a patient prior to the administration of a drug. PDx's proprietary technology can be universally applied to finding the genetic causes to any inherited or sporadic genetic disease. When applied to personalizing medicine, the technology standardizes the pharmaceutical industry's approach to generating clinically useful genetic profiles used to prescreen and segregate patients for targeted medicines. PDx's proprietary knowledge of genetic triggers, otherwise known as ""causative DNA biomarkers"", are the key ingredients in medical diagnostics and companion tests. These exclusive predictive tests are marketed directly to the medical community and they place PDx in prime position to (i) transform how physicians diagnose and manage disease in their patients, (ii) enable pharmaceutical companies to market drugs with higher efficacy and safety and (iii) satisfy insurance companies with lower costs of healthcare. "

More>>

<<Less